<p>Abivax SA will be added to the Nasdaq Biotechnology Index (NBI) effective prior to market open on December 22, 2025. The addition reflects the company’s progress, particularly in advancing obefazimod through successful Phase 3 trials for ulcerative colitis, and its increased visibility in the global biotechnology community. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001145774-en) on December 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

ABVX

<p>Abivax SA will be added to the Nasdaq Biotechnology Index on December 22, 2025, reflecting its progress in advancing obefazimod through successful Phase 3 trials for ulcerative colitis and increased visibility in the global biotechnology community.</p>

Abivax SA Joins Nasdaq Biotechnology Index